Clinical Trials Logo

Pregnancy Outcome clinical trials

View clinical trials related to Pregnancy Outcome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03215368 Active, not recruiting - Child Development Clinical Trials

The Ma'Anshan Birth Cohort (MABC)

Start date: May 16, 2013
Phase:
Study type: Observational

The Ma'anshan Birth Cohort (MABC) is a population-based prospective pregnancy and birth cohort study that aims to explore the early environmental and genetic determinants of maternal and child health, with a focus on health outcomes including maternal health, children's cognitive and behavioral development, growth and physical development, video-screen behaviors, and asthma and allergic diseases. MABC was officially launched in May 2013 at the Ma'anshan Maternal and Child Health Hospital in Anhui Province, and a total of 3,474 families were recruited as of September 2014 to continuously track the health status of mother-child pairs during pregnancy, delivery, and childhood, including basic family demographics, maternal pregnancy and birth history and past history, history of exposure to hazardous factors during pregnancy, children's diets and lifestyles, and children's physical and cognitive-behavioral development, MABC quantifies the attributional relationship between environmental chemicals, diet and nutrition, drug safety, psychological stress, lifestyle, biorhythm, endocrine metabolism and adverse birth outcomes, birth defects, neurodevelopmental disorders, developmental disabilities, etc., and identifies environmental, behavioral and genetic causative factors for birth defects and common developmental disorders, and identifies early warning signs and symptoms for early detection of birth defects. genetic causative factors, identify clinical biomarkers with early predictive effects, integrate and form a precise risk evaluation and early warning model, carry out regional comprehensive prevention and treatment applications, and promote the improvement of the quality of the birth population. Currently, MABC is conducting its 20th school-age follow-up visit.

NCT ID: NCT03113331 Active, not recruiting - Pregnancy Outcome Clinical Trials

The 3D Cohort Study (Design, Develop, Discover)

3D
Start date: May 25, 2010
Phase:
Study type: Observational

The 3D Cohort Study (Design, Develop, Discover) was established to help bridge knowledge gaps about the links between various adverse exposures during pregnancy with birth outcomes and later health outcomes in children.

NCT ID: NCT02271490 Active, not recruiting - Pregnancy Outcome Clinical Trials

Acrosome Reaction Induction Prior to ICSI

RA-ICSI
Start date: June 2014
Phase: N/A
Study type: Interventional

Introduction To get through the egg vestment and fertilize the oocyte, the spermatozoon uses its acrosomal enzymes. When Intracytoplasmic sperm microinjection (ICSI) is performed, the acrosomal enzymes are introduced with the spermatozoa inside the ooplasme. The fate of these enzymes, that normally never enter the oocyte, is not known. But they impair the embryo development. Indeed, although the ICSI outcome is satisfactory in humans, a series of studies in many species (mouse, hamster, cattle, and horse) demonstrate the deleterious effects of the introduction of acrosomal material in the oocyte cytoplasm, on embryo and fetal development. These studies have also shown two things: - The bigger the acrosome, the more deleterious are the effects of their introduction into the egg. - And that the induction of the acrosome reaction (AR) prior to ICSI significantly improves embryonic development and the number of babies born after embryo transfer as it is the case in the mouse. The microinjection of acrosome reacted sperm increases from 40 to 70 % the percentage of pups born per embryo transferred. Hypothesis : It is possible to improve ICSI outcome, in terms of babies born in human, by induction of the AR prior to microinjection. After studying several techniques, we choose a physiologic technique for acrosome induction. The induction of acrosome reaction prior to ICSI should improve in utero fetal development and decrease the rate of miscarriage and pregnancy arrest.

NCT ID: NCT01768247 Active, not recruiting - Pregnancy Outcome Clinical Trials

HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)

Start date: January 2012
Phase: Phase 4
Study type: Interventional

A thin endometrium is one of the most difficult problems encountered in assisted reproduction every day practice Regarding the proliferative phase, several ways of treatment have been undertaken to circumvent thin endometrium trying to increase thickness with questionable results. The objective of the current study will be whether a daily dose of 150 IU (international units) of human chorionic gonadotropin (HCG) for seven days concomitant with estrogen administration in estrogen replacement cycles can increase the endometrial thickness and improve pregnancy outcome.